HU204700B - Process for producing aqueous compositions comprising piperidinyl cyclopentylheptenoic acid derivatives - Google Patents
Process for producing aqueous compositions comprising piperidinyl cyclopentylheptenoic acid derivatives Download PDFInfo
- Publication number
- HU204700B HU204700B HU886537A HU653788A HU204700B HU 204700 B HU204700 B HU 204700B HU 886537 A HU886537 A HU 886537A HU 653788 A HU653788 A HU 653788A HU 204700 B HU204700 B HU 204700B
- Authority
- HU
- Hungary
- Prior art keywords
- cyclodextrin
- compound
- hydrochloride salt
- water
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878729823A GB8729823D0 (en) | 1987-12-22 | 1987-12-22 | Complexes |
| GB888804422A GB8804422D0 (en) | 1988-02-25 | 1988-02-25 | Complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT50040A HUT50040A (en) | 1989-12-28 |
| HU204700B true HU204700B (en) | 1992-02-28 |
Family
ID=26293226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU886537A HU204700B (en) | 1987-12-22 | 1988-12-21 | Process for producing aqueous compositions comprising piperidinyl cyclopentylheptenoic acid derivatives |
Country Status (29)
| Country | Link |
|---|---|
| JP (1) | JPH02210A (sv) |
| KR (1) | KR890009402A (sv) |
| CN (1) | CN1034132A (sv) |
| AT (1) | AT395943B (sv) |
| AU (1) | AU615245B2 (sv) |
| BE (1) | BE1001704A3 (sv) |
| CA (1) | CA1328078C (sv) |
| CH (1) | CH676665A5 (sv) |
| DE (1) | DE3843059A1 (sv) |
| DK (1) | DK712888A (sv) |
| ES (1) | ES2011727A6 (sv) |
| FI (1) | FI885920A (sv) |
| FR (1) | FR2624731B1 (sv) |
| GB (1) | GB2211737B (sv) |
| GR (1) | GR880100854A (sv) |
| HU (1) | HU204700B (sv) |
| IE (1) | IE61995B1 (sv) |
| IL (1) | IL88764A0 (sv) |
| IT (1) | IT1224835B (sv) |
| LU (1) | LU87411A1 (sv) |
| MY (1) | MY103952A (sv) |
| NL (1) | NL8803126A (sv) |
| NO (1) | NO885689L (sv) |
| NZ (1) | NZ227446A (sv) |
| PH (1) | PH24982A (sv) |
| PL (1) | PL276595A1 (sv) |
| PT (1) | PT89301B (sv) |
| SE (1) | SE502288C2 (sv) |
| ZW (1) | ZW18088A1 (sv) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814725D0 (en) * | 1988-06-21 | 1988-07-27 | Glaxo Group Ltd | Medicaments |
| AU616571B2 (en) * | 1988-10-28 | 1991-10-31 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
| IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| KR100825736B1 (ko) * | 2005-12-07 | 2008-04-29 | 한국전자통신연구원 | 무선 ｘｍｌ 전자 서명 서비스 제공 장치 및 그 방법 |
| KR100832740B1 (ko) * | 2007-01-17 | 2008-05-27 | 한국과학기술원 | 분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (sv) * | 1970-06-10 | 1975-02-04 | ||
| JPS5443569B2 (sv) * | 1972-07-05 | 1979-12-20 | ||
| HU181703B (en) * | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
| JPS57183772A (en) * | 1981-04-29 | 1982-11-12 | Glaxo Group Ltd | Aminocyclopentanol acids and esters, manufacture and medicinal composition |
| JPS58116423A (ja) * | 1981-12-28 | 1983-07-11 | Sumitomo Chem Co Ltd | メタノプロスタサイクリン製剤組成物 |
| JPS58192821A (ja) * | 1982-04-30 | 1983-11-10 | Dainippon Pharmaceut Co Ltd | 脳神経細胞の酸素欠乏性疾患の治療剤 |
| JPS5946228A (ja) * | 1982-09-08 | 1984-03-15 | Zeria Shinyaku Kogyo Kk | 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法 |
| JPS5973576A (ja) * | 1982-09-16 | 1984-04-25 | グラクソ・グル−プ・リミテツド | ピペリジニルシクロペンタノ−ルヘプテン酸塩 |
| GB2127406B (en) * | 1982-09-16 | 1986-03-05 | Glaxo Group Ltd | Piperidinlycyclopentanolheptenoic acid salt |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| JPS60150039A (ja) * | 1984-01-17 | 1985-08-07 | Minolta Camera Co Ltd | 水陸両用固定焦点カメラ |
| DE3504044A1 (de) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel |
| JPS6327440A (ja) * | 1986-07-18 | 1988-02-05 | Sanraku Inc | グルコシル化分岐シクロデキストリン含有組成物 |
-
1988
- 1988-12-21 JP JP63320759A patent/JPH02210A/ja active Pending
- 1988-12-21 BE BE8801423A patent/BE1001704A3/fr not_active IP Right Cessation
- 1988-12-21 PL PL27659588A patent/PL276595A1/xx unknown
- 1988-12-21 NL NL8803126A patent/NL8803126A/nl not_active Application Discontinuation
- 1988-12-21 DK DK712888A patent/DK712888A/da not_active Application Discontinuation
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/ko not_active Application Discontinuation
- 1988-12-21 GR GR880100854A patent/GR880100854A/el unknown
- 1988-12-21 NZ NZ227446A patent/NZ227446A/xx unknown
- 1988-12-21 IT IT8848702A patent/IT1224835B/it active
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 NO NO88885689A patent/NO885689L/no unknown
- 1988-12-21 FI FI885920A patent/FI885920A/fi not_active Application Discontinuation
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 DE DE3843059A patent/DE3843059A1/de not_active Ceased
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 ES ES8803876A patent/ES2011727A6/es not_active Expired - Fee Related
- 1988-12-21 FR FR8816902A patent/FR2624731B1/fr not_active Expired - Fee Related
- 1988-12-21 SE SE8804607A patent/SE502288C2/sv not_active IP Right Cessation
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-21 AT AT0313088A patent/AT395943B/de not_active IP Right Cessation
- 1988-12-21 CN CN88108916A patent/CN1034132A/zh active Pending
- 1988-12-21 PT PT89301A patent/PT89301B/pt not_active IP Right Cessation
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 HU HU886537A patent/HU204700B/hu not_active IP Right Cessation
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/xx unknown
- 1988-12-21 LU LU87411A patent/LU87411A1/fr unknown
- 1988-12-22 IL IL88764A patent/IL88764A0/xx not_active IP Right Cessation
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3576180B2 (ja) | 改良イフォスファミド凍結乾燥組成物 | |
| HU211937A9 (en) | Indole derivatives | |
| KR101731155B1 (ko) | 안정화된 보리코나졸 조성물 | |
| BG64272B1 (bg) | 'Ъ''АВИ, 'ЪДЪРЖА(tm)И ПРО'ИВОГЪБИ-НО 'Р...Д''ВО И А-...'А'...Н Б""...Р | |
| US4036954A (en) | Stable prostaglandin E group-containing formulation | |
| HU217300B (hu) | Kristályos, vízmentes mikofenolát-mofetil sók, a vegyületet tartalmazó intravénás gyógyászati készítmények és előállításuk | |
| EP0833640B1 (en) | Pharmaceutical composition containing lamotrigine | |
| JP3253302B2 (ja) | ３−ジアルキルアミノエトキシベンゾイル−ベンゾフランを含有する非経口溶液 | |
| HU204700B (en) | Process for producing aqueous compositions comprising piperidinyl cyclopentylheptenoic acid derivatives | |
| US4092428A (en) | Process of preparing stable prostaglandin E group-containing formulation | |
| US4968673A (en) | Use of a thromboxane receptor antagonist in renal diseases and dysfunction | |
| US4772589A (en) | Etoposide solution in NMP | |
| US5084480A (en) | Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia | |
| US5221695A (en) | Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin | |
| JPS6146454B2 (sv) | ||
| US5015648A (en) | Use of a thromboxane receptor antagonist in pregnancy-induced hypertension and related conditions | |
| JPS6216929B2 (sv) | ||
| JPH0343251B2 (sv) | ||
| US4322424A (en) | Crystalline glucoconate salt of m-AMSA and compositions containing same | |
| MXPA04011777A (es) | Composicion farmaceutica. | |
| US4626541A (en) | Water soluble salt composition of m-AMSA | |
| JPH032862B2 (sv) | ||
| JP2005521670A (ja) | ゾニポリドメシレート医薬組成物及びゾニポリドの溶解度を改善する方法 | |
| HU198622B (en) | Process for producing stable, injectable, antemetic composition | |
| EP0342030A2 (en) | Use of a thromboxane receptor antagonist to complement arterial surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |